
Sign up to save your podcasts
Or


Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831
By BMJ Group4.6
88 ratings
Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831

136 Listeners

320 Listeners

495 Listeners

36 Listeners

50 Listeners

302 Listeners

5 Listeners

8 Listeners

5 Listeners

3 Listeners

2 Listeners

3 Listeners

40 Listeners

15 Listeners

1 Listeners

49 Listeners

0 Listeners

6 Listeners

14 Listeners

3 Listeners

12 Listeners

3 Listeners

22 Listeners

23 Listeners

24 Listeners

132 Listeners

50 Listeners

179 Listeners

6 Listeners

823 Listeners

80 Listeners